

CERTIFICATE OF PARTICIPATION

Survey of 24 April 2020

You have participated in the External Quality Assessment with the following analysis

Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen) (346):
Screening test anti-HCV and combined detection anti-HCV and HCV antigen (R: B2)

(R) analysis is subject to the RiliBÄK

Participant:
29607
MDL Bodimed-99 Ltd.
Buzludja
1606 Sofia

Düsseldorf, 29 May 2020



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Heinz Zeichhardt
(Adviser)

CERTIFICATE

Survey of 28 April 2020

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Virus Genome Detection - Coronaviruses (340):


Validity 12 months:

SARS-CoV-2 (RNA) - qualitative

(R) analysis is subject to the RiliBÄK

Participant:
29607
MDL Bodimed-99 Ltd.
Buzludja
1606 Sofia

Düsseldorf, 01 May 2020



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Heinz Zeichhardt
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 28 April 2020

You have participated in the External Quality Assessment with the following analysis

Virus Genome Detection - Coronaviruses (340):

SARS-CoV-2 (RNA) - qualitative

(R) analysis is subject to the RiLiBAK

Participant:
29607
MDL Bodimed-99 Ltd.
Buzludja
1606 Sofia

Düsseldorf, 01 May 2020



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Heinz Zeichhardt
(Adviser)

INSTAND

Gesellschaft zur Förderung der Qualitätssicherung
in medizinischen Laboratorien e.V.
Ubiestr. 20 | 40223 Düsseldorf

CERTIFICATE OF PARTICIPATION

Survey of 27 November 2020

You have participated in the External Quality Assessment with the following analysis

Virus Genome Detection - Hepatitis B Virus Program 1 (361):

HBV (DNA) - quantitative (R: B3)

Virus Genome Detection - Hepatitis C Virus Program 1 (362):

HCV (RNA) - quantitative (R: B3)

(R) analysis is subject to the RiliBÄK

Participant:
29607
MDL Bodimed-99 Ltd.
Buzludja
1606 Sofia

Düsseldorf, 22 December 2020



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Heinz Zeichhardt
(Adviser)

CERTIFICATE

Survey of 27 November 2020

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Virus Genome Detection - Hepatitis B Virus Program 1 (361):

Validity 12 months:

HBV (DNA) - quantitative (R: B3)

Virus Genome Detection - Hepatitis C Virus Program 1 (362):

Validity 12 months:

HCV (RNA) - quantitative (R: B3)

(R) analysis is subject to the RilibÄK

Participant:
29607
MDL Bodimed-99 Ltd.
Buzludja
1606 Sofia



Düsseldorf, 22 December 2020

Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

Prof. Dr. rer. nat. Heinz Zeichhardt
(Adviser)

CERTIFICATE

Survey of 29 January 2021

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Tumor Markers (292):

Validity 6 months:

PSA, total (R: B1a)

hCG intact +beta-hCG (R: B1a)

Validity 12 months:

CA 125

CA 72-4

PSA, free

ROMA-Score

S100

beta-2-Microglobulin

human Epididymis Protein 4

neuronspecific Enolase

(R) analysis is subject to the RiliBÄK

Participant:

29607

MDL Bodimed-99 Ltd.

Buzludja

1606 Sofia



Düsseldorf, 12 February 2021

Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

Prof. Dr. med. Stefan Holdenrieder
(Adviser)

CERTIFICATE

Survey of 24 April 2020

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Virus Immunology - Hepatitis C Virus (Ab and HCV Antigen) (346):

Validity 12 months:

Screening test anti-HCV and combined detection anti-HCV and HCV antigen (R: B2)

(R) analysis is subject to the RiitBÁK

Participant:
29607
MDL Bodimed-99 Ltd.
Buzludja
1606 Sofia

Düsseldorf, 29 May 2020



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. rer. nat. Heinz Zeichhardt
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 29 January 2021

You have participated in the External Quality Assessment with the following analysis

Tumor Markers (292):

CA 125
CA 72-4
CYFRA 21-1
PSA, free
PSA, total (R: B1a)
ROMA-Score
S100
beta-2-Microglobulin
hCG intact +beta-hCG (R: B1a)
human Epididymis Protein 4
neuronspecific Enolase

(R) analysis is subject to the RiLiBÄK

Participant:
29607
MDL Bodimed-99 Ltd.
Buzludja
1606 Sofia



Düsseldorf, 12 February 2021

Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

Prof. Dr. med. Stefan Holdenrieder
(Adviser)